| Literature DB >> 25825544 |
Kikuro Fukushima1, Norie Ito2, Graham R Barnes3, Sachiyo Onishi2, Nobuyoshi Kobayashi2, Hidetoshi Takei4, Peter M Olley2, Susumu Chiba2, Kiyoharu Inoue2, Tateo Warabi2.
Abstract
While retinal image motion is the primary input for smooth-pursuit, its efficiency depends on cognitive processes including prediction. Reports are conflicting on impaired prediction during pursuit in Parkinson's disease. By separating two major components of prediction (image motion direction memory and movement preparation) using a memory-based pursuit task, and by comparing tracking eye movements with those during a simple ramp-pursuit task that did not require visual memory, we examined smooth-pursuit in 25 patients with Parkinson's disease and compared the results with 14 age-matched controls. In the memory-based pursuit task, cue 1 indicated visual motion direction, whereas cue 2 instructed the subjects to prepare to pursue or not to pursue. Based on the cue-information memory, subjects were asked to pursue the correct spot from two oppositely moving spots or not to pursue. In 24/25 patients, the cue-information memory was normal, but movement preparation and execution were impaired. Specifically, unlike controls, most of the patients (18/24 = 75%) lacked initial pursuit during the memory task and started tracking the correct spot by saccades. Conversely, during simple ramp-pursuit, most patients (83%) exhibited initial pursuit. Popping-out of the correct spot motion during memory-based pursuit was ineffective for enhancing initial pursuit. The results were similar irrespective of levodopa/dopamine agonist medication. Our results indicate that the extra-retinal mechanisms of most patients are dysfunctional in initiating memory-based (not simple ramp) pursuit. A dysfunctional pursuit loop between frontal eye fields (FEF) and basal ganglia may contribute to the impairment of extra-retinal mechanisms, resulting in deficient pursuit commands from the FEF to brainstem.Entities:
Keywords: Extra‐retinal mechanisms; Parkinson's disease; memory; priming effects; smooth‐pursuit
Year: 2015 PMID: 25825544 PMCID: PMC4393177 DOI: 10.14814/phy2.12361
Source DB: PubMed Journal: Physiol Rep ISSN: 2051-817X
Clinical characteristics. Patient (Pt) # 1–30. Age in years. Medication indicates anti-parkinsonian medication
| Pt No. | Age/sex | H-Y stage | UPDRS part 3 | Duration | Main clinical symptoms | Brain MRI | MMSE | FAB | Medication, daily dose (mg) | Initial Pursuit | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MP | SR | ||||||||||
| 1 | 56/F | 3 | 11 | 3 years | Lt. resting tremor | Normal | 29 | 14 | No drug | − | + |
| 2 | 56/M | 3 | 16 | 7 years | Bradykinesia, Lt. rigidity, REM sleep disorder | Bil. BG lacunar infarct. | 29 | 18 | No drug | + | + |
| 3 | 57/F | 1 | 14 | 1.5 years | Lt. rigidity, resting tremor | Normal | 30 | 17 | No drug | + | + |
| 4 | 59/F | 3 | 3 | 4.5 years | Gait festination, freezing Lt. rigidity | Normal | 26 | 16 | LeBe 200/50, En 200, Pr 2.5 | − | − |
| 5 | 64/F | 3 | 28 | 4 years | Lt. rigidity, resting tremor | Normal | 30 | 14 | LeBe 150/37.5, Pr 0.75 | − | + |
| 6 | 65/M | 3 | 21 | 1 year | Gait festination | Normal | 25 | 15 | No drug | + | + |
| 7 | 66/M | 3 | 17 | 6 years | Gait freezing, Lt. resting tremor, rigidity | Lt. arachnoid cyst | 27 | 15 | LeCa 200/20, Pr 2, En 300, Dr 300 | − | + |
| 8 | 70/F | 3 | 36 | 3 years | Rt. rigidity, resting tremor | Normal | 26 | 16 | LeCa 300/30, Pr 2.5 | + | + |
| 9 | 70/F | 3 | 24 | 11 years | Flexed posture to rt. | Normal | 23 | 14 | LeCa 450/112.5,Tri 4, Se 5, Per 1.125, En 400 | + | + |
| 10 | 72/M | 2 | 16 | 2 years | Bradykinesia | Normal | 30 | 17 | LeBe 300/75 | + | + |
| 11 | 73/F | 2 | 23 | 1 year | Rt. rigidity | Normal | 28 | 15 | No drug | − | + |
| 12 | 74/F | 2.5 | 13 | 4 years | Lt. rigidity | Normal | 28 | 15 | LeBe 150/37.5, Pr 0.5 | − | + |
| 13 | 75/F | 3.5 | 45 | 2 years | Rt. resting tremor, Forward flexed posture | Normal | 24 | 16 | Ro 4 | − | + |
| 14 | 75/M | 3 | Not tested | 6.5 years | Bradykinesia | Not tested | 26 | 15 | LeCa 600/60, Pr 2 | − | − |
| 15 | 77/F | 3 | 31 | 9 years | Gait freezing | Normal | 30 | 18 | LeBe 300/75, Pr 2.5 | − | Not tested |
| 16 | 77/F | 3 | 29 | 7 years | Flexed posture to rt., Rt. resting tremor, Dyskinesia | Normal | 26 | 16 | LeBe 300/75, Pr 2, En 300, Am 50 | − | − |
| 17 | 77/M | 3 | 13 | 4 years | Gait freezing, Bil. rigidity | Normal | 29 | 15 | LeBe 300/75, Am 250, Se 7.5, Dr 300 | − | − |
| 18 | 78/F | 3 | 23 | 1 year | Rt. resting tremor | Bil. BG lacunar infarct. | 25 | 15 | LeCa 300/30, Pr 1.5 | − | + |
| 19 | 79/M | 3 | 30 | 1 year | Gait festination, Lt. rigidity | Normal | 28 | 14 | LeBe 200/50, Pr 1, Am 100 | − | + |
| 20 | 80/M | 4 | 32 | 22 years | Rt. resting | Bil. BG lacunar infarct. | 30 | 15 | LeCa 350/35, Ro 9, Am 100, Se 7.5, Dr 600, En 300, Donepezile 5 | − | + |
| 21 | 83/M | 3.5 | 24 | 5 years | Gait festination, freezing, Rt. resting tremor, rigidity | Normal | 29 | 13 | LeBe 400/100, Pr 2, En 400 | − | + |
| 22 | 84/M | 3.5 | 53 | 2 years | Gait festination | Normal | 24 | 14 | LeCa400/40 | − | + |
| 23 | 86/M | 3.5 | 29 | 4 years | Gait festination, Hallucination | Small bleeding in Rt. putamen | 21 | 11 | Pr 0.125 | − | + |
| 24 | 87/F | 2 | 28 | 2 m | Gait festination, Rt. rigidity, resting tremor | Bil. BG lacunar infarct. | 20 | 12 | No drug | − | + |
| 25 | 80/F | 3 | 31 | 5 years | Lt. resting tremor | Normal | 25 | 10 | Ro 0.25, LeCa 200/20, Dr 300 | − | − |
| 26 | 71/F | 3 | 20 | 1 year | Gait festination | Lacunar infarct. around bil. lateral ventricles | 24 | 13 | No drug | Not tested | + |
| 27 | 78/F | 2.5 | 13 | 2 m | Forward flexed posture, Gait dfestination | Normal | 23 | 11 | No drug | Not tested | + |
| 28 | 77/F | 3.5 | 31 | 2 years | Bil. resting tremor, Bradykinesia | Mild atrophy of cerebral cortex | 22 | 8 | LeBe 400/100 | Not tested | + |
| 29 | 78/M | 3.5 | 30 | 9 years | Lt. resting tremor, Rt. hand rigidity | Normal | 25 | 12 | LeBe 500/125, Rp 1, Dr 200, En 600 | Not tested | − |
| 30 | 80/M | 3 | 28 | 11 years | Gait freezing | Normal | 28 | 7 | Am 150, En 300, LeCa 300/30, Dr 400 | Not tested | − |
No drug indicates that patients received no anti-parkinsonian medication prior to this study. + and − in Initial pursuit indicate presence and absence, respectively, of initial pursuit during memory-based pursuit (MP) and simple ramp-pursuit (SR).
F, female; M, male; H-Y, Hoehn–Yahr; y and m, disease duration in years (y) or months (m); Lt. left. Rt; right. BG, basal ganglia; Bil, bilateral; REM, rapid eye movement; MMSE, mini-mental state examination; FAB, frontal assessment battery; MP, memory-based pursuit; SR, simple ramp-pursuit; UPDRS, unified Parkinson's disease rating scale; Am, amantadine; Dr, droxidopa; En, entacapone; LeBe, levodopa-benserazide; LeCa, levodopa-carbidopa; Per, Pergolide mesilate; Pr, pramipexole; Ro, ropinirole; Se, selegiline; Tri, trihexyphenidyl hydrochloride.
Figure 1Task conditions and eye movements of a patient with Parkinson's disease aged 74. (A) memory-based pursuit task conditions. (B1–3) sorted eye position traces to cue 1/cue 2 directions/instructions as indicated. See text for further explanation.
Figure 2Eye movements of a patient with Parkinson's disease and a control subject. (A and B) eye position and velocity traces of the same patient shown in Figure1B during simple ramp-pursuit (A) and memory-based pursuit (B). (C and D) eye position and desaccaded eye velocity and averaged eye velocity of a control subject aged 85. Rightward and leftward eye movement traces are superimposed in A4, B4 and C2–4, and D2–4 as indicated. In C1, rightward and leftward spot position traces are superimposed. C4 and D4 plot desaccaded and averaged eye velocities for rightward and leftward, separately, during simple ramp-pursuit (C4) and memory-based pursuit (D4) with linear interpolation of the desaccaded portions. See text for further explanation.
Figure 3Comparison of movement parameters of patients with Parkinson's disease and control subjects during memory-based pursuit and simple ramp-pursuit. Aa plots % of initial pursuit appearance in each subject group in each task as indicated. Ab-G plot mean + SD values of different movement parameters (ordinates) for patients with Parkinson's disease (solid) and control subjects (open) in each task as indicated. Number of patients tested during memory-based pursuit and simple ramp-pursuit are 24 and 23 in Aa, 6 and 19 in Ab, 24 and 23 in B–G. Number of controls tested are 14 during each task in A–G. See text for further explanation.
Figure 4Initial pursuit latencies of individual subjects during simple ramp-pursuit (SR) and memory-based pursuit (MP) and normalized latency differences. (A and B) initial pursuit latencies (from spot motion onset) of six patients who showed initial pursuit during memory-based pursuit (A) and 14 age-matched controls (B). C–D, normalized latency difference (MP–SR) of the six patients (C) and 14 age-matched control subjects (D). For comparison, (E) shows normalized latency difference of young subjects, data taken from Ito et al. (2013a). Values of the same subjects are connected by lines. Open squares connected with dashed lines indicate means.
Figure 5Comparison of eye velocity time courses of patients with Parkinson's disease and normal controls. (A and C) blue, green, and red traces are mean ± SEM desaccaded eye velocity of 10 patients (A) and 10 controls (C) during simple ramp-pursuit (SR), memory-based pursuit (MP) and popping-out of the correct spot during memory-based pursuit (Pop). (B and D) pursuit acceleration of the 10 patients (B) and 10 controls (D) during the three task conditions for the 1st 100 m after response onset. Error bars indicate one SEM. For further explanation, see text.